Skip to main content

Advertisement

SpringerLink
Log in

Association between clinically relevant toxicities of pazopanib and sunitinib and the use of weak CYP3A4 and P-gp inhibitors

  • Pharmacoepidemiology and Prescription
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Sunitinib and pazopanib, two tyrosine kinase inhibitors (TKI), may be targets of potential pharmacokinetic drug-drug interactions (P-PK-DDIs). While strong cytochrome P4503A (CYP3A4) inhibitors or inducers should cause a clinically relevant modification in plasma TKI concentrations, the effect of weak inhibitors is unknown. The objective of this study was to evaluate the association between weak P-PK-DDI and clinically relevant toxicity in real life.

Patients and methods

This was a single-center retrospective study including patients treated with sunitinib or pazopanib for any malignancies, for whom a PK-DDI analysis was performed before starting TKI. The primary endpoint was the correlation between P-PK-DDIs and a dose decrease after 1 month of treatment. The secondary endpoint was the correlation between PK-DDIs and drug withdrawal due to toxicity.

Results

Seventy-six patients were assessed. A P-PK-DDI with weak CYP3A4 or P-gp inhibition was found in 14 patients. In patients with P-PK-DDI or without, the dose was reduced during the first month in 57.1% and 17.7% (p = 0.003) and the drug withdrawn in 42.8% and 11.3% (p = 0.011), respectively. In multivariate analysis, a significant correlation was found between P-PK-DDI (CYP3A4 and P-gp inhibitors) and dose reduction, and between drug withdrawal and PK-DDI (CYP3A4 inhibitors).

Conclusion

P-PK-DDI was correlated with dose reduction and drug withdrawal due to toxicity. The causality of this relationship warrants to be assessed; therefore, therapeutic drug monitoring is necessary in patients treated with TKI.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data availability

The dataset analyzed during the present study is available from the corresponding author on request.

References

  1. Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J et al (2013) Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369:722–731. https://doi.org/10.1056/NEJMoa1303989

    Article  CAS  PubMed  Google Scholar 

  2. van der Graaf WTA, Blay J-Y, Chawla SP, Kim D-W, Bui-Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP, Beppu Y, le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji MR, Coens C, Demetri GD, Fletcher CD, Dei Tos AP, Hohenberger P, EORTC Soft Tissue and Bone Sarcoma Group, PALETTE study group (2012) Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379:1879–1886. https://doi.org/10.1016/S0140-6736(12)60651-5

    Article  CAS  PubMed  Google Scholar 

  3. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329–1338. https://doi.org/10.1016/S0140-6736(06)69446-4

    Article  CAS  PubMed  Google Scholar 

  4. Raymond E, Dahan L, Raoul J-L, Bang Y-J, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Hörsch D, Hammel P, Wiedenmann B, van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501–513. https://doi.org/10.1056/NEJMoa1003825

    Article  CAS  PubMed  Google Scholar 

  5. Shao J, Markowitz JS, Bei D, An G (2014) Enzyme- and transporter-mediated drug interactions with small molecule tyrosine kinase inhibitors. J Pharm Sci 103:3810–3833. https://doi.org/10.1002/jps.24113

    Article  CAS  PubMed  Google Scholar 

  6. Boudou-Rouquette P, Tlemsani C, Blanchet B, Huillard O, Jouinot A, Arrondeau J, Thomas-Schoemann A, Vidal M, Alexandre J, Goldwasser F (2016) Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review. Expert Opin Drug Metab Toxicol 12:1433–1444. https://doi.org/10.1080/17425255.2016.1225038

    Article  CAS  PubMed  Google Scholar 

  7. Thomas-Schoemann A, Blanchet B, Bardin C, Noé G, Boudou-Rouquette P, Vidal M et al (2014) Drug interactions with solid tumour-targeted therapies. Crit Rev Oncol Hematol 89:179–196. https://doi.org/10.1016/j.critrevonc.2013.08.007

    Article  PubMed  Google Scholar 

  8. Tang SC, Lagas JS, Lankheet NAG, Poller B, Hillebrand MJ, Rosing H, Beijnen JH, Schinkel AH (2012) Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration. Int J Cancer 130:223–233. https://doi.org/10.1002/ijc.26000

    Article  CAS  PubMed  Google Scholar 

  9. Tan AR, Gibbon DG, Stein MN, Lindquist D, Edenfield JW, Martin JC, Gregory C, Suttle AB, Tada H, Botbyl J, Stephenson JJ (2013) Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors. Cancer Chemother Pharmacol 71:1635–1643. https://doi.org/10.1007/s00280-013-2164-3

    Article  CAS  PubMed  Google Scholar 

  10. Kollmannsberger C, Soulieres D, Wong R, Scalera A, Gaspo R, Bjarnason G (2007) Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can Urol Assoc J 1:S41–S54

    CAS  PubMed  PubMed Central  Google Scholar 

  11. US Food and Drug Administration, Center for Drug Evaluation and Research. Pazopanib clinical pharmacology and biopharmaceutics review 2008

  12. Sun L, Liang C, Shirazian S, Zhou Y, Miller T, Cui J, Fukuda JY, Chu JY, Nematalla A, Wang X, Chen H, Sistla A, Luu TC, Tang F, Wei J, Tang C (2003) Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem 46:1116–1119. https://doi.org/10.1021/jm0204183

    Article  CAS  PubMed  Google Scholar 

  13. Bilbao-Meseguer I, Jose BS, Lopez-Gimenez LR, Gil MA, Serrano L, Castaño M, Sautua S, Basagoiti AD, Belaustegui A, Baza B, Baskaran Z, Bustinza A (2015) Drug interactions with sunitinib. J Oncol Pharm Pract 21:52–66. https://doi.org/10.1177/1078155213516158

    Article  CAS  PubMed  Google Scholar 

  14. Despiau F, Bombail M, Leches C, Montastruc M, Gladieff L, Delord J-P (2015) Nurse telephone support at home during chemotherapy. Rev Infirm:37–39. https://doi.org/10.1016/j.revinf.2015.06.011

  15. Loue C, Tod M (2014) Reliability and extension of quantitative prediction of CYP3A4-mediated drug interactions based on clinical data. AAPS J 16:1309–1320. https://doi.org/10.1208/s12248-014-9663-y

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Mickey RM, Greenland S (1989) The impact of confounder selection criteria on effect estimation. Am J Epidemiol 129:125–137. https://doi.org/10.1093/oxfordjournals.aje.a115101

    Article  CAS  PubMed  Google Scholar 

  17. Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, Gschwend JE, de Giorgi U, Parikh O, Hawkins R, Sevin E, Négrier S, Khan S, Diaz J, Redhu S, Mehmud F, Cella D (2014) Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study. J Clin Oncol 32:1412–1418. https://doi.org/10.1200/JCO.2013.50.8267

    Article  CAS  PubMed  Google Scholar 

  18. Bowlin SJ, Xia F, Wang W, Robinson KD, Stanek EJ (2013) Twelve-month frequency of drug-metabolizing enzyme and transporter-based drug-drug interaction potential in patients receiving oral enzyme-targeted kinase inhibitor antineoplastic agents. Mayo Clin Proc 88:139–148. https://doi.org/10.1016/j.mayocp.2012.10.020

    Article  CAS  PubMed  Google Scholar 

  19. Voll ML, Yap KD, Terpstra WE, Crul M (2010) Potential drug-drug interactions between anti-cancer agents and community pharmacy dispensed drugs. Pharm World Sci 32:575–580. https://doi.org/10.1007/s11096-010-9410-0

    Article  CAS  PubMed  Google Scholar 

  20. van Leeuwen RWF, Brundel DHS, Neef C, van Gelder T, Mathijssen RHJ, Burger DM, Jansman FG (2013) Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs. Br J Cancer 108:1071–1078. https://doi.org/10.1038/bjc.2013.48

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Frampton JE (2017) Pazopanib: a review in advanced renal cell carcinoma. Target Oncol 12:543–554. https://doi.org/10.1007/s11523-017-0511-8

    Article  PubMed  Google Scholar 

  22. Heinze G, Dunkler D (2017) Five myths about variable selection. Transpl Int 30:6–10. https://doi.org/10.1111/tri.12895

    Article  PubMed  Google Scholar 

  23. Sperandei S (2014) Understanding logistic regression analysis. Biochem Med (Zagreb) 24:12–18. https://doi.org/10.11613/BM.2014.003

    Article  Google Scholar 

  24. Suttle AB, Ball HA, Molimard M, Hutson TE, Carpenter C, Rajagopalan D, Lin Y, Swann S, Amado R, Pandite L (2014) Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma. Br J Cancer 111:1909–1916. https://doi.org/10.1038/bjc.2014.503

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Cabel L, Blanchet B, Thomas-Schoemann A, Huillard O, Bellesoeur A, Cessot A, Giroux J, Boudou-Rouquette P, Coriat R, Vidal M, Saidu NEB, Golmard L, Alexandre J, Goldwasser F (2018) Drug monitoring of sunitinib in patients with advanced solid tumors: a monocentric observational French study. Fundam Clin Pharmacol 32:98–107. https://doi.org/10.1111/fcp.12327

    Article  CAS  PubMed  Google Scholar 

  26. Krasulova K, Holas O, Anzenbacher P (2017) Influence of amlodipine enantiomers on human microsomal cytochromes P450: stereoselective time-dependent inhibition of CYP3A enzyme activity. Molecules 22. https://doi.org/10.3390/molecules22111879

  27. Ohyama K, Nakajima M, Suzuki M, Shimada N, Yamazaki H, Yokoi T (2000) Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions. Br J Clin Pharmacol 49:244–253

    Article  CAS  Google Scholar 

  28. Zhou S-F, Xue CC, Yu X-Q, Li C, Wang G (2007) Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 29:687–710. https://doi.org/10.1097/FTD.0b013e31815c16f5

    Article  CAS  PubMed  Google Scholar 

  29. Ito K, Brown HS, Houston JB (2004) Database analyses for the prediction of in vivo drug-drug interactions from in vitro data. Br J Clin Pharmacol 57:473–486. https://doi.org/10.1111/j.1365-2125.2003.02041.x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Verheijen RB, Swart LE, Beijnen JH, Schellens JHM, Huitema ADR, Steeghs N (2017) Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization. Cancer Chemother Pharmacol 80:1171–1178. https://doi.org/10.1007/s00280-017-3463-x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Lankheet NAG, Kloth JSL, Gadellaa-van Hooijdonk CGM, Cirkel GA, Mathijssen RHJ, Lolkema MPJK et al (2014) Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours. Br J Cancer 110:2441–2449. https://doi.org/10.1038/bjc.2014.194

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Widmer N, Bardin C, Chatelut E, Paci A, Beijnen J, Levêque D, Veal G, Astier A (2014) Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies. Eur J Cancer 50:2020–2036. https://doi.org/10.1016/j.ejca.2014.04.015

    Article  CAS  PubMed  Google Scholar 

  33. Verheijen RB, Yu H, Schellens JHM, Beijnen JH, Steeghs N, Huitema ADR (2017) Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology. Clin Pharmacol Ther 102:765–776. https://doi.org/10.1002/cpt.787

    Article  PubMed  PubMed Central  Google Scholar 

  34. Riechelmann RP, Moreira F, Smaletz O, Saad ED (2005) Potential for drug interactions in hospitalized cancer patients. Cancer Chemother Pharmacol 56:286–290. https://doi.org/10.1007/s00280-004-0998-4

    Article  PubMed  Google Scholar 

  35. Puts MTE, Costa-Lima B, Monette J, Girre V, Wolfson C, Batist G, Bergman H (2009) Medication problems in older, newly diagnosed cancer patients in Canada: how common are they? A prospective pilot study. Drugs Aging 26:519–536. https://doi.org/10.2165/00002512-200926060-00008

    Article  PubMed  Google Scholar 

  36. Lalani A-KA, Li H, Heng DYC, Wood L, Kalirai A, Bjarnason GA et al (2017) First-line sunitinib or pazopanib in metastatic renal cell carcinoma: the Canadian experience. Can Urol Assoc J 11:112–117. https://doi.org/10.5489/cuaj.4398

    Article  PubMed  PubMed Central  Google Scholar 

  37. Lee C-K, Choi J-S, Choi D-H (2015) Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors. Pharmacol Rep 67:44–51. https://doi.org/10.1016/j.pharep.2014.08.005

    Article  CAS  PubMed  Google Scholar 

  38. Kamiyama E, Nakai D, Mikkaichi T, Okudaira N, Okazaki O (2010) Interaction of angiotensin II type 1 receptor blockers with P-gp substrates in Caco-2 cells and hMDR1-expressing membranes. Life Sci 86:52–58. https://doi.org/10.1016/j.lfs.2009.11.006

    Article  CAS  PubMed  Google Scholar 

  39. Weiss J, Dormann S-MG, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE (2003) Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 305:197–204. https://doi.org/10.1124/jpet.102.046532

    Article  CAS  PubMed  Google Scholar 

  40. Klotz U (2002) Interaction potential of lercanidipine, a new vasoselective dihydropyridine calcium antagonist. Arzneimittelforschung 52:155–161. https://doi.org/10.1055/s-0031-1299873

    Article  CAS  PubMed  Google Scholar 

  41. de Jonge MJA, Hamberg P, Verweij J, Savage S, Suttle AB, Hodge J, Arumugham T, Pandite LN, Hurwitz HI (2013) Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors. Investig New Drugs 31:751–759. https://doi.org/10.1007/s10637-012-9885-8

    Article  CAS  Google Scholar 

  42. Ha VH, Ngo M, Chu MP, Ghosh S, Sawyer MB, Chambers CR (2015) Does gastric acid suppression affect sunitinib efficacy in patients with advanced or metastatic renal cell cancer? J Oncol Pharm Pract 21:194–200. https://doi.org/10.1177/1078155214527145

    Article  CAS  PubMed  Google Scholar 

  43. Lalani A-KA, McKay RR, Lin X, Simantov R, Kaymakcalan MD, Choueiri TK (2017) Proton pump inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 15:724–732. https://doi.org/10.1016/j.clgc.2017.05.019

    Article  PubMed  Google Scholar 

  44. McAlister RK, Aston J, Pollack M, Du L, Koyama T, Chism DD (2018) Effect of concomitant pH-elevating medications with pazopanib on progression-free survival and overall survival in patients with metastatic renal cell carcinoma. Oncologist 23:686–692. https://doi.org/10.1634/theoncologist.2017-0578

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Mir O, Touati N, Lia M, Litière S, Le Cesne A, Sleijfer S et al (2019) Impact of concomitant administration of gastric acid-suppressive agents and pazopanib on outcomes in soft-tissue sarcoma patients treated within the EORTC 62043/62072 trials. Clin Cancer Res 25:1479–1485. https://doi.org/10.1158/1078-0432.CCR-18-2748

    Article  PubMed  Google Scholar 

  46. van Leeuwen RWF, Jansman FGA, Hunfeld NG, Peric R, Reyners AKL, Imholz ALT, Brouwers JRBJ, Aerts JG, van Gelder T, Mathijssen RHJ (2017) Tyrosine kinase inhibitors and proton pump inhibitors: An evaluation of treatment options. Clin Pharmacokinet 56:683–688. https://doi.org/10.1007/s40262-016-0503-3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Agarwal M, Thareja N, Benjamin M, Akhondi A, Mitchell GD (2018) Tyrosine kinase inhibitor-induced hypertension. Curr Oncol Rep 20:65–10. https://doi.org/10.1007/s11912-018-0708-8

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmacy department IUCT (Institut Universitaire du Cancer) Oncopole, Institut Claudius Regaud, 1 avenue Irène Joliot-Curie, Toulouse CEDEX 9, 31059, France

    Camille Azam, Pauline Claraz, Camille Vinson, Véronique Pelagatti & Florent Puisset

  2. Oncology department IUCT (Institut Universitaire du Cancer) Oncopole, Institut Claudius Regaud, 1 avenue Irène Joliot-Curie, Toulouse CEDEX 9, 31059, France

    Christine Chevreau, Ewa Cottura, Loïc Mourey, Damien Pouessel, Selena Guibaud, Olivia Pollet, Magali Le Goff & Catherine Bardies

  3. Pharmacy department IUCT (Institut Universitaire du Cancer) Oncopole, Centre Hospitalier Universitaire, 1 avenue Irène Joliot-Curie, Toulouse CEDEX 9, France

    Jean Marie Canonge

  4. Centre de Recherches en Cancérologie de Toulouse (CRCT), Team 14, INSERM UMR1037, Université de Toulouse, 2 avenue Hubert Curien, CS53717, Toulouse CEDEX 1, France

    Florent Puisset

Authors
  1. Camille Azam
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pauline Claraz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christine Chevreau
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Camille Vinson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ewa Cottura
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Loïc Mourey
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Damien Pouessel
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Selena Guibaud
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Olivia Pollet
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Magali Le Goff
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Catherine Bardies
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Véronique Pelagatti
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Jean Marie Canonge
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Florent Puisset
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Florent Puisset.

Ethics declarations

The study was performed in compliance with ethical standards.

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval for retrospective study

As a retrospective study, no informed consent was required but patients were informed that their data could be used for clinical evaluation. None refused.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

ESM 1

(DOCX 36 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Azam, C., Claraz, P., Chevreau, C. et al. Association between clinically relevant toxicities of pazopanib and sunitinib and the use of weak CYP3A4 and P-gp inhibitors. Eur J Clin Pharmacol 76, 579–587 (2020). https://doi.org/10.1007/s00228-020-02828-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-020-02828-w

Keywords

Search

Navigation